A global pharmaceutical client required delivery of an urgent global site transfer of its affected product portfolio following the sale of one of its key manufacturing sites to a third party.
A hard deadline due to the third party taking over the site and a legal change to the Manufacturing Authorisation, meant a non-flexible 3 month timeline from brief to implementation had to be met.